AnGes

AnGes MG,Inc. Global leader in gene Medical

Select Language

NAVIGATION
  • Home
  • For Investors
For Investors

IR
2019.02.12 AnGes and Kamada entered into agreement for the commercialization of HGF gene therapy product in Israel
2018.04.12 AnGes Announces First Patient Treated with DNA Vaccine for Hypertension in Phase I / II Clinical Study in Australia
2018.02.27 AnGes Announces First Patient Treated with NF-kappa B Decoy in Phase Ib Study to Treat Discogenic Low Back Pain
2018.01.22 AnGes Submits Application for Marketing Approval to PMDA for HGF gene therapy for Critical Limb Ischemia
2016.10.03 Summary of Announcement Regarding Issue of Stock Acquisition Rights
Completion of 28th Series of Stock Acquisition Rights (Private Placement) (with Option to Revise Exercise Price)
2016.08.05 Summary of Announcement Regarding Issue of Stock Acquisition Rights
28th Series of Stock Acquisition Rights(Private Placement) (with Option to Revise Exercise Price)
2016.08.01 AnGes Announces Investment in Vical
2016.07.12 AnGes to Start Development of Next-Generation Decoy Oligonucleotide
--Fundamental Technologies Established for STAT 6/NF-kB Chimera Decoy as a Treatment for Inflammatory Diseases--
2016.07.05 AnGes Announces Top-Line Results for Japanese Phase III Clinical Trial of NF-κB Decoy Oligonucleotide for Atopic Dermatitis
2016.06.20 AnGes Announces Amendment to the Global Development of HGF Plasmid for Critical Limb Ischemia
2016.06.16 AnGes Announces a Basic Agreement with Morishita Jintan for the Exclusive Development, Manufacturing, and Marketing Rights of CIN Therapeutic Vaccine
2016.04.18 Summary of the Announcement Regarding the Issue of Stock Acquisition Rights
2016.03.25 Summary of the Announcement Regarding the Issue of Stock Acquisition Rights
2016.01.19 Completion of Patient Enrollment in the Phase III Clinical Trials of NF-kB Decoy Oligonucleotide Ointment Drug for Atopic Dermatitis in Japan
2015.09.07 Last Patient Out in Clinical Trial of the NF-κB Decoy Oligo Coated PTA Balloon Catheter for Hemodialysis Shunts
For Investors
  • To receive Email Alerts
  • To receive Email Alerts
  • IR related information of AnGes is also available on IR Street
  • IR Street
  • Shared Research Report

page top

  • News Release
  • About AnGes
  • Projects
  • For Investors
  • HomeSite mapPrivacy PolicySite PolicyContact
  • Copyright© AnGes, Inc. All Rights Reserved.